1. Home
  2. HYPR vs RFL Comparison

HYPR vs RFL Comparison

Compare HYPR & RFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

HOLD

Current Price

$1.00

Market Cap

104.0M

Sector

Health Care

ML Signal

HOLD

Logo Rafael Holdings Inc. Class B

RFL

Rafael Holdings Inc. Class B

HOLD

Current Price

$1.46

Market Cap

54.4M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYPR
RFL
Founded
2014
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Real Estate
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
54.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HYPR
RFL
Price
$1.00
$1.46
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$1.28
N/A
AVG Volume (30 Days)
594.5K
143.0K
Earning Date
11-13-2025
12-11-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,591,000.00
$1,029,000.00
Revenue This Year
$5.17
N/A
Revenue Next Year
$35.44
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
47.63
52 Week Low
$0.53
$1.17
52 Week High
$2.22
$3.19

Technical Indicators

Market Signals
Indicator
HYPR
RFL
Relative Strength Index (RSI) 43.62 64.11
Support Level $0.85 $1.21
Resistance Level $1.10 $1.60
Average True Range (ATR) 0.08 0.08
MACD 0.01 0.04
Stochastic Oscillator 44.59 67.44

Price Performance

Historical Comparison
HYPR
RFL

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

Share on Social Networks: